Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Understanding Health Literacy Among Patients with Thalassemia: A Global Patient Survey by the Thalassemia Advocacy Advisory Council

Sujit Sheth, Lily Cannon, Laurice M Levine, Ralph Colasanti, Jill Deitrick, Tobias Larkin, Dina Steagall, Eleni Michalaki, Holly John, Keely S Gilroy, Louise Lombard, Maria Domenica Cappellini

Blood (2024) 144 (Supplement 1): 7949.

https://doi.org/10.1182/blood-2024-203302

Published: 2024

Journal Articles

Efficacy and Safety of Combination Therapy with Oral Iron Chelators Deferiprone and Deferasirox in Patients with β-Thalassemia Major: A Systematic Literature Review

Janet L. Kwiatkowski, Sujit Sheth, Antonis Kattamis, Francesco Bianchi, Fernando Tricta, Caroline Fradette, Roberta Luzzi, Antonio Piga

Blood (2024) 144 (Supplement 1): 5268.

https://doi.org/10.1182/blood-2024-207562

Published: 2024

Journal Articles

Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Blood (2024) 144 (Supplement 1): 512.

https://doi.org/10.1182/blood-2024-205779

Published: 2024

Journal Articles

ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Blood (2024) 144 (Supplement 1): 409.

https://doi.org/10.1182/blood-2024-200867

Published: 2024

Journal Articles

Analysis of the Risk of Infection Stratified By Absolute Neutrophil Counts during Deferiprone-Associated Severe Neutropenia or Agranulocytosis

Sherif M. Badawy, Jan Palmblad, Fernando Tricta, Noemi Toiber Temin, Caroline Fradette, Leo Lin, Anna Rozova, Sujit Sheth

Blood (2023) 142 (Supplement 1): 2501.

https://doi.org/10.1182/blood-2023-181963

Published: 2023

Journal Articles

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Blood (2023) 142 (Supplement 1): 1053.

https://doi.org/10.1182/blood-2023-190534

Published: 2023

Journal Articles

Improvement of Underlying Disease Pathophysiology of Ineffective Erythropoiesis in Non-Transfusion-Dependent (NTD) Patients with β-Thalassemia Receiving Luspatercept: Biomarker Analysis from the BEYOND Trial

Manuel Ugidos Guerrero, Sujit Sheth, Olivier Hermine, Sadanand Vodala

Blood (2023) 142 (Supplement 1): 1104.

https://doi.org/10.1182/blood-2023-179122

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept in Patients Enrolled in the BELIEVE Trial: Data from the Phase 3b Long-Term Rollover Study

Maria Domenica Cappellini, Ali T Taher, Vip Viprakasit, Pencho Georgiev, Kevin H.M. Kuo, Natalia Holot, Valérie Vilmont, Loyse Felber Medlin, Wen-Ling Kuo, Yinzhi Lai, Luciana Moro Bueno, Sujit Sheth

Blood (2023) 142 (Supplement 1): 3849.

https://doi.org/10.1182/blood-2023-174089

Published: 2023

Journal Articles

Investigating Health Literacy in Thalassemia: Founding a Patient-Led Research Approach

Sujit Sheth, Ralph Colasanti, Lily Cannon, Jill Deitrick, Holly John, Keely S Gilroy, Louise Lombard, Eleni Michalaki, Tobias Larkin, Laurice M Levine, Dina Steagall, Maria Domenica Cappellini

Blood (2023) 142 (Supplement 1): 5251.

https://doi.org/10.1182/blood-2023-181629

Published: 2023

Journal Articles

Real-World Characteristics, Treatment Utilization, and Transfusion Burden in Patients with β-Thalassemia Initiating Luspatercept: A US Cohort Study

Sujit Sheth, Mrudula B. Glassberg, Jana Lee, Queeny Ip, Jingyuan (Hannah) Liu, Luciana Moro Bueno

Blood (2023) 142 (Supplement 1): 2476.

https://doi.org/10.1182/blood-2023-173378

Published: 2023

Journal Articles

Association of Hemoglobin Levels with Healthcare Resource Utilization and Costs in Non-Transfusion-Dependent α- and β-Thalassemia: A Retrospective Observational Study Using Real-World Data

Arielle L Langer, Amey Rane, Louise Lombard, Keely S Gilroy, Junlong Li, Jing Zhao, Carolyn R Lew, Brian M Davis, Ryan Ross, Sujit Sheth

Blood (2023) 142 (Supplement 1): 5244.

https://doi.org/10.1182/blood-2023-189236

Published: 2023

Journal Articles

Initial Results in a Phase 1b Trial of PB-04 in Sickle Cell Disease Demonstrate Fetal Hemoglobin Induction, Additive Activity with Hydroxyurea, and Improved Red Blood Cell Sickling Parameters

Kevin H.M. Kuo, Sylvia Titi Singer, Gershwin Theophilus Blyden, Lanetta Bronté-Hall, Aidan Faller, Abdullah Kutlar, Frans A. Kuypers, Aliya U. Zaidi, Patrick C. Hines, Niren Patel, Sandra Larkin, Hanny Al-Samkari, Sujit Sheth, Seyed Mehdi Nouraie, Susan Perrine

Blood (2023) 142 (Supplement 1): 1148.

https://doi.org/10.1182/blood-2023-184627

Published: 2023

Journal Articles

Setting Industry Standards for Patient Engagement, Partnership, Allyship and Care: The Patient Vision Project

Biree Andemariam, Tamara Schryver, Rae Blaylark, Ralph Colasanti, Nirmish Shah, Charles R. Jonassaint, Rucha Shah, Cassandra Trimnell, Teonna Woolford, Janie Davis, Eva Gallagher, Ahmar U Zaidi, Holly John, Sujit Sheth

Blood (2023) 142 (Supplement 1): 7233.

https://doi.org/10.1182/blood-2023-181791

Published: 2023

Journal Articles

Cross-Community Collaboration and Data Collection to Optimize Patient Care in Hemolytic Anemias

Blood (2023) 142 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2023-181632

Published: 2023

Journal Articles

Burden of Illness of Alpha- and Beta-Thalassemia: A Qualitative Study

Sujit Sheth, Alexander K Glaros, Mona Martin, Cristina Abel, William R Lenderking, Susan Morris, Keely S Gilroy, Kevin H.M. Kuo

Blood (2023) 142 (Supplement 1): 7329.

https://doi.org/10.1182/blood-2023-189367

Published: 2023

Journal Articles

Clinical Burden of Alpha- and Beta-Thalassemia Compared to Matched Controls in the Real-World Setting

Arielle L. Langer, Louise Lombard, Keely Gilroy, Junlong Li, Jing Zhao, Carolyn R. Lew, Erin Bullock, Brian M Davis, Sujit Sheth

Blood (2022) 140 (Supplement 1): 5362–5364.

https://doi.org/10.1182/blood-2022-167265

Published: 2022

Journal Articles

Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study

Sujit Sheth, Olivier Hermine, Ali T. Taher, Kevin H.M. Kuo, John B. Porter, Antonio Piga, Thomas D. Coates, Antonis Kattamis, Loyse Felber Medlin, Wen-Ling Kuo, Natalia Holot, Maria Domenica Domenica Cappellini

Blood (2022) 140 (Supplement 1): 1946–1948.

https://doi.org/10.1182/blood-2022-157511

Published: 2022

Journal Articles

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Blood (2022) 140 (Supplement 1): 4899–4901.

https://doi.org/10.1182/blood-2022-166881

Published: 2022

Journal Articles

The Benefits Trial of PB-04 to Evaluate Safety, PK, and Preliminary Efficacy in Inducing Fetal Globin Expression in Beta Thalassemia Intermedia and Sickle Cell Disease

Kevin H.M. Kuo, Sylvia Singer, Sujit Sheth, Hanny Al-Samkari, Gershwin Blyden, Lanetta Bronte-Hall, Betty S. Pace, Abdullah Kutlar, Franciscus A. Kuypers, Aidan D Faller, Seyed Mehdi Nouraie, Pramod Terse, Haksong Jin, Xin Xu, Asaf Alimardanov, Arthur J. Sytkowski, Sharie Haugabook, Susan P Perrine

Blood (2021) 138 (Supplement 1): 4159.

https://doi.org/10.1182/blood-2021-148909

Published: 2021

Journal Articles

Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease

Ashutosh Lal, R. Clark Clark Brown, Thomas D. Coates, Theodosia A. Kalfa, Janet L. Kwiatkowski, Julie Brevard, Von Potter, Ken W. Wood, Sujit Sheth

Blood (2021) 138 (Supplement 1): 4162.

https://doi.org/10.1182/blood-2021-145752

Published: 2021

NARROW

Understanding Health Literacy Among Patients with Thalassemia: A Global Patient Survey by the Thalassemia Advocacy Advisory Council

Efficacy and Safety of Combination Therapy with Oral Iron Chelators Deferiprone and Deferasirox in Patients with β-Thalassemia Major: A Systematic Literature Review

Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Analysis of the Risk of Infection Stratified By Absolute Neutrophil Counts during Deferiprone-Associated Severe Neutropenia or Agranulocytosis

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Improvement of Underlying Disease Pathophysiology of Ineffective Erythropoiesis in Non-Transfusion-Dependent (NTD) Patients with β-Thalassemia Receiving Luspatercept: Biomarker Analysis from the BEYOND Trial

Efficacy and Safety of Luspatercept in Patients Enrolled in the BELIEVE Trial: Data from the Phase 3b Long-Term Rollover Study

Investigating Health Literacy in Thalassemia: Founding a Patient-Led Research Approach

Real-World Characteristics, Treatment Utilization, and Transfusion Burden in Patients with β-Thalassemia Initiating Luspatercept: A US Cohort Study

Association of Hemoglobin Levels with Healthcare Resource Utilization and Costs in Non-Transfusion-Dependent α- and β-Thalassemia: A Retrospective Observational Study Using Real-World Data

Initial Results in a Phase 1b Trial of PB-04 in Sickle Cell Disease Demonstrate Fetal Hemoglobin Induction, Additive Activity with Hydroxyurea, and Improved Red Blood Cell Sickling Parameters

Setting Industry Standards for Patient Engagement, Partnership, Allyship and Care: The Patient Vision Project

Cross-Community Collaboration and Data Collection to Optimize Patient Care in Hemolytic Anemias

Burden of Illness of Alpha- and Beta-Thalassemia: A Qualitative Study

Clinical Burden of Alpha- and Beta-Thalassemia Compared to Matched Controls in the Real-World Setting

Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

The Benefits Trial of PB-04 to Evaluate Safety, PK, and Preliminary Efficacy in Inducing Fetal Globin Expression in Beta Thalassemia Intermedia and Sickle Cell Disease

Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only